ClinicalTrials.gg
CompletedNCT02863705Updated Aug 31, 2018

Efficacy and Safety of COMBIGAN® in Korean Patients With Primary Open Angle Glaucoma (POAG) and Normal Tension Glaucoma (NTG)

A Phase 4 interventional study of brimonidine tartrate/timolol malate Ophthalmic Solution and bimatoprost ophthalmic solution 0.01% in Glaucoma, Open-Angle and Normal Tension Glaucoma, sponsored by Allergan. Completed at 9 sites in Korea, Republic of. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2018-08-31.

Sponsored by Allergan (part of AbbVie) · Phase 4, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 4
Study type
Interventional
Enrollment
118
Allocation
Non-randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 58 studies in Glaucoma, Open-Angle by AbbVie — 1 open to participants now, 3 under way, 1 of them phase 3. Glaucoma, Open-Angle · AbbVie.

Enrollment
24th of 34
118 · median 164
Started
2016
the only one that year
Phase 4
14 of 58
none open now
Registered
49th of 58
by date

Among the 58 studies in Glaucoma, Open-Angle by AbbVie, this one is the 24th largest by enrollment of the 34 interventional ones that give a count, is the only one that started in 2016, is one of 14 in phase 4, and was the 49th registered.

Glaucoma, Open-Angle

924 studies on the registry are indexed under Glaucoma, Open-Angle; 115 are open to participants now.

Browse Glaucoma, Open-Angle studies →

Open to participants now

1 of the 58 studies in Glaucoma, Open-Angle by AbbVie is open now, in 1 country. Recruiting first, the newest first:

By country, each count listing its studies:

Who these studies take

Of the 82 Glaucoma, Open-Angle studies recruiting now, 63 (77%) set no upper age limit and 5 (6%) stop at 75 or younger; 5 take children under 18; 11 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 58 studies in Glaucoma, Open-Angle by AbbVie, or all of them as a file.
02

Study summary

The objective of this study is to evaluate the long-term efficacy and safety of COMBIGAN® (brimonidine tartrate/timolol malate) in patients only using COMBIGAN® (brimonidine tartrate/timolol malate) and also in patients who require additional IOP lowering with LUMIGAN® (bimatoprost) 0.01%.

03

Conditions studied

  • Glaucoma, Open-Angle
  • Normal Tension Glaucoma
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Patients with Primary open angle glaucoma (Regardless of Intraocular pressure)
  • Previous history of topical beta-blocker use and insufficiently controlled IOP

Exclusion criteria

Exclusion Criteria:

  • Pigmentary or exfoliative glaucoma
  • History of angle-closure or an occludable angle by gonioscopy
  • Prior filtration or laser iridotomy
  • Argon laser trabeculoplasty or Selective laser trabeculoplasty performed less than 6 months
  • History or signs of chronic inflammatory eye disease, ocular trauma, or potentially progressive retinal disease
05

Study design

Phase
Phase 4
Primary purpose
Treatment
Allocation
Non-randomized
Intervention model
Single group
Masking
None (open label)
Enrollment
118 participants (actual)

Study arms

  • Experimental
    COMBIGAN®

    One drop of COMBIGAN® in the affected eye, administered twice daily for 12 months

    Drug: brimonidine tartrate/timolol malate Ophthalmic Solution

  • Experimental
    COMBIGAN® + LUMIGAN® 0.01%

    LUMIGAN® will be administered once daily in the evening 5 minutes after COMBIGAN® instillation in patients who require additional IOP lowering.

    Drug: brimonidine tartrate/timolol malate Ophthalmic Solution · Drug: bimatoprost ophthalmic solution 0.01%

Interventions

  • Drugbrimonidine tartrate/timolol malate Ophthalmic Solution

    One drop of brimonidine tartrate/timolol malate (COMBIGAN®) Ophthalmic Solution in the affected eye, administered twice daily for 12 months

  • Bimatoprost ophthalmic solution 0.01% (LUMIGAN®) administered once daily in the evening 5 minutes after COMBIGAN® instillation if additional lowering IOP is needed

06

What researchers measure

Primary outcomes

  1. Mean IOP change from Baseline (11AM point)

    Time frame: Baseline, Month 12

Secondary outcomes

  1. Mean IOP change from Baseline (11AM point)

    Mean IOP change from baseline (11AM point) in the following patient sub-groups 1. patients with NTG 2. patients with POAG 3. patients taking Combigan alone 4. patients taking Combigan plus additional Lumigan 0.01%

    Time frame: Baseline, Month 12

  2. Mean IOP change from Baseline (9AM point)

    Mean IOP change from baseline (9AM point) in the following patient sub-groups 1. patients with NTG 2. patients with POAG 3. patients taking Combigan alone 4. patients taking Combigan plus additional Lumigan 0.01%

    Time frame: Baseline, Month 12

  3. Mean change in Mean deviation (MD) from Baseline

    Time frame: Baseline, Month 12

  4. Mean change in Pattern standard deviation (PSD) from Baseline

    Time frame: Baseline, Month 12

  5. Mean change in Visual field index (VFI) from Baseline

    Time frame: Baseline, Month 12

  6. Mean change in cup to disc ratio (C/D ratio) from Baseline

    Time frame: Baseline, Month 12

  7. Rate of VF progression measured as change in VF index over time

    Rate of VF progression during 12 months in the following patient sub-groups. 1. patients with NTG 2. patients with POAG 3. patients taking Combigan alone 4. patients taking Combigan plus additional Lumigan 0.01%

    Time frame: Baseline, Month 12

  8. Mean duration of achieving the target IOP with COMBIGAN® alone

    Time frame: 12 Months

  9. The percentage of subjects of achieving the target IOP with COMBIGAN® alone during 12 months

    Time frame: 12 Months

  10. Definition of patient demographics (descriptive analysis of age and gender)

    Define patient demographics in the following patient sub-groups: 1. patients with NTG 2. patients with POAG 3. patients taking Combigan alone 4. patients taking Combigan plus additional Lumigan 0.01%

    Time frame: Baseline, Month 12

07

Study locations

9 sites
  • Pusan National University Hospital, Pusan National University School of Medicine
    Busan, 49241, Korea, Republic of
  • Yeungnam University Hospital, Yeungnam University College of Medicine
    Daegu, 42415, Korea, Republic of
  • Chungnam National University Hospital, Chungnam National University College of Medicine
    Daejeon, 35015, Korea, Republic of
  • Chonnam National University Hospital, Chonnam National University Medical School
    Gwangju, 61469, Korea, Republic of
  • Seoul National University Bundang Hospital, Seoul National University College of Medicine
    Gyeonggi-do, 13619, Korea, Republic of
  • Seoul National University Hospital, Seoul National University College of Medicine
    Seoul, 03080, Korea, Republic of
  • Kangbuk Samsung Medical Center, Sungkyunkwan University School of Medicine
    Seoul, 03181, Korea, Republic of
  • Seoul St. Mary's Hospital, The Catholic University of Korea College of Medicine
    Seoul, 06591, Korea, Republic of
  • Kim's Eye Hospital, Konyang University College of Medicine
    Seoul, 07301, Korea, Republic of
08

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Jul 2016 to primary completion in Jul 2018, 24 months.

Of 45 phase 4 interventional studies under Glaucoma, Open-Angle, half reached primary completion within 20 months of starting (the median), counting those still running; a quarter within 14 and three quarters within 37. This study's 24 months is above that.

How these figures are worked out, and which studies are left out of them.

Registered
May 2, 2016
First posted
Aug 11, 2016
StartActual
Jul 5, 2016
Primary completionActual
Jul 25, 2018
CompletionActual
Jul 25, 2018
Last update
Aug 31, 2018
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Aug 31, 2018, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT02863705
Lead sponsor
Allergan
Responsible party
Sponsor
First posted
Aug 11, 2016
Start date
Jul 5, 2016
Primary completion
Jul 25, 2018
Completion
Jul 25, 2018
Last update
Aug 31, 2018

Study contacts

Joy Maglambayan
study director · Allergan

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Aug 2018. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Bimatoprost Ophthalmic Solution

Start the discussion